$ORIC
Oric Pharmaceuticals, Inc. Stock $oric

$oric Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-K Financial Statement

#000156459021014865 Filed on March 23, 2021

Income Statement

Concept	2021 Q1	2020 Q4	2019 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.860M	$4.300M	$1.810M
YoY Change	151.81%	137.57%
% of Gross Profit
Research & Development	$11.70M	$12.11M	$6.960M
YoY Change	61.25%	73.99%
% of Gross Profit
Depreciation & Amortization	$229.0K	$230.0K	$270.0K
YoY Change	-8.4%	-14.81%
% of Gross Profit
Operating Expenses	$16.55M	$16.41M	$8.770M
YoY Change	80.34%	87.12%
Operating Profit	-$16.55M
YoY Change	80.34%
Interest Expense	$44.00K	$30.00K	$340.0K
YoY Change	-81.74%	-91.18%
% of Operating Profit
Other Income/Expense, Net	$44.00K	-$10.00K	$70.00K
YoY Change	-85.67%	-114.29%
Pretax Income	-$16.51M	-$28.26M	-$8.350M
YoY Change	86.13%	238.44%
Income Tax
% Of Pretax Income
Net Earnings	-$16.51M	-$28.26M	-$8.350M
YoY Change	86.08%	238.44%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$450.1K	-$838.6K	-$79.87K
COMMON SHARES
Basic Shares Outstanding	36.70M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q1	2020 Q4	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$278.1M	$293.6M	$89.16M
YoY Change	250.25%	229.3%
Cash & Equivalents	$104.2M	$78.45M	$89.16M
Short-Term Investments	$173.9M	$215.2M	$0.00
Other Short-Term Assets	$2.000M	$3.100M
YoY Change	150.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$280.1M	$296.7M	$90.00M
YoY Change	249.12%	229.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.969M	$1.981M	$2.241M
YoY Change	-6.06%	-11.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.890M	$319.0K	$1.853M
YoY Change	-30.0%	-82.78%
Total Long-Term Assets	$3.859M	$2.300M	$4.094M
YoY Change	-20.76%	-43.82%
TOTAL ASSETS
Total Short-Term Assets	$280.1M	$296.7M	$90.00M
Total Long-Term Assets	$3.859M	$2.300M	$4.094M
Total Assets	$284.0M	$299.0M	$94.09M
YoY Change	233.68%	217.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$606.0K	$757.0K	$152.0K
YoY Change	-24.25%	398.03%
Accrued Expenses	$7.070M	$8.245M	$5.202M
YoY Change	102.0%	58.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.676M	$9.002M	$5.354M
YoY Change	59.92%	68.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$209.0K	$219.0K
YoY Change	-65.17%
Total Long-Term Liabilities	$209.0K	$219.0K
YoY Change	-65.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.676M	$9.002M	$5.354M
Total Long-Term Liabilities	$209.0K	$219.0K
Total Liabilities	$7.885M	$9.221M	$6.119M
YoY Change	46.02%	50.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$182.9M	-$166.4M	-$92.69M
YoY Change		79.52%
Common Stock	$459.0M	$456.2M	$2.606M
YoY Change		17405.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$276.1M	$289.8M	-$90.08M
YoY Change
Total Liabilities & Shareholders Equity	$284.0M	$299.0M	$94.09M
YoY Change	233.68%	217.77%

Cashflow Statement

Concept	2021 Q1	2020 Q4	2019 Q4
OPERATING ACTIVITIES
Net Income	-$16.51M	-$28.26M	-$8.350M
YoY Change	86.08%	238.44%
Depreciation, Depletion And Amortization	$229.0K	$230.0K	$270.0K
YoY Change	-8.4%	-14.81%
Cash From Operating Activities	-$14.90M	-$17.83M	-$7.140M
YoY Change	79.99%	149.72%
INVESTING ACTIVITIES
Capital Expenditures	$182.0K	-$410.0K	-$60.00K
YoY Change	4450.0%	583.33%
Acquisitions
YoY Change
Other Investing Activities	$40.83M	-$90.84M	$0.00
YoY Change	21389.47%
Cash From Investing Activities	$40.65M	-$91.26M	-$60.00K
YoY Change	21406.35%	152000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	16.00K	125.5M	-70.00K
YoY Change	-100.98%	-179371.43%
NET CHANGE
Cash From Operating Activities	-14.90M	-17.83M	-7.140M
Cash From Investing Activities	40.65M	-91.26M	-60.00K
Cash From Financing Activities	16.00K	125.5M	-70.00K
Net Change In Cash	25.76M	16.40M	-7.270M
YoY Change	-365.12%	-325.58%
FREE CASH FLOW
Cash From Operating Activities	-$14.90M	-$17.83M	-$7.140M
Capital Expenditures	$182.0K	-$410.0K	-$60.00K
Free Cash Flow	-$15.08M	-$17.42M	-$7.080M
YoY Change	82.1%	146.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2606000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92690000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	289776000
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001796280
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	us-gaap	Operating Loss Carryforwards Expiration Date OperatingLossCarryforwardsExpirationDate	2034-12-31
CY2020	oric	Cumulative Change In Ownership Period CumulativeChangeInOwnershipPeriod	P3Y
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19278606
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0317
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-90084000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	298997000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	94093000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-90084000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.027
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0559
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.026
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.030
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8801
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2020	dei	City Area Code CityAreaCode	650
CY2020	dei	Local Phone Number LocalPhoneNumber	388-5600
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2020	dei	Trading Symbol TradingSymbol	ORIC
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.77
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.93
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9511
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.04
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.98
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-39269
CY2020	dei	Entity Registrant Name EntityRegistrantName	ORIC PHARMACEUTICALS, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1787157
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	240 E. Grand Ave
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	2nd Floor
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	743300000
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36695019
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78446000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89159000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	215154000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3097000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	840000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	296697000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	89999000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1981000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2241000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	319000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	152000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1853000
CY2020Q4	us-gaap	Assets Assets	298997000
CY2019Q4	us-gaap	Assets Assets	94093000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	757000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8245000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5202000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9002000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5354000
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	219000
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	765000
CY2020Q4	us-gaap	Liabilities Liabilities	9221000
CY2019Q4	us-gaap	Liabilities Liabilities	6119000
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	20348788
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	19278606
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19278606
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	178058000
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	178058000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	26750000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36672415
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36672415
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1984222
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1984222
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	456196000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-166393000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	35921000
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	22844000
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	19026000
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	24843000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13422000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5725000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3345000
CY2020	us-gaap	Operating Expenses OperatingExpenses	74186000
CY2019	us-gaap	Operating Expenses OperatingExpenses	28569000
CY2018	us-gaap	Operating Expenses OperatingExpenses	22371000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-74186000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-28569000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-22371000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	306000
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1397000
CY2020	us-gaap	Profit Loss ProfitLoss	-73703000
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	775000
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	177000
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	289000
CY2018	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	233000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21942476
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1899348
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1734115
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-43611000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	79000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	469000
CY2018	us-gaap	Profit Loss ProfitLoss	-21363000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	483000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1686000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-64426000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	131000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1094000
CY2019	us-gaap	Profit Loss ProfitLoss	-26883000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	178058000
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	19843000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	443000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5278000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-31000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	289776000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-73703000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-26883000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21363000
CY2020	us-gaap	Depreciation Depreciation	970000
CY2019	us-gaap	Depreciation Depreciation	1028000
CY2018	us-gaap	Depreciation Depreciation	903000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1008000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-73703000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-26883000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21363000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-31000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73734000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26883000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21363000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.36
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-14.15
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-12.32
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5278000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1094000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	469000
CY2020	oric	Non Cash Stock Consideration Acquisition NonCashStockConsiderationAcquisition	19843000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-8000
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-15000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-299000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2258000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-234000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	297000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4303000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	986000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-410000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45268000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23533000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20683000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	667000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	768000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	525000
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	225485000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10000000
CY2020	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	193000
CY2018	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	17000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-215959000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-768000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-508000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	138000000
CY2020	oric	Payments Of Stock Issuance Costs With Initial Public Offering PaymentsOfStockIssuanceCostsWithInitialPublicOffering	12691000
CY2019	oric	Payments Of Stock Issuance Costs With Initial Public Offering PaymentsOfStockIssuanceCostsWithInitialPublicOffering	99000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	133308000
CY2020	oric	Payments Of Stock Issuance Costs With Public Offering PaymentsOfStockIssuanceCostsWithPublicOffering	8546000
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	70792000
CY2018	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	37929000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	443000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	131000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	79000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	250514000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70824000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38008000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10713000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	46523000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16817000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89159000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42636000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25819000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78446000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89159000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42636000
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	178058000
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	43000
CY2019	oric	Unpaid Deferred Financing Costs UnpaidDeferredFinancingCosts	1244000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. <span style="text-decoration:underline;">Description of the Business</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORIC Pharmaceuticals, Inc. (ORIC or the Company) is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by <span style="font-style:italic;text-decoration:underline;">O</span><span style="font-style:italic;">vercoming </span><span style="font-style:italic;text-decoration:underline;">R</span><span style="font-style:italic;">esistance </span><span style="font-style:italic;text-decoration:underline;">I</span><span style="font-style:italic;">n </span><span style="font-style:italic;text-decoration:underline;">C</span><span style="font-style:italic;">ancer</span>. The Company was incorporated in Delaware in August 2014 and has offices in South San Francisco and San Diego, California. The Company’s principal operations are in the United States and the Company operates in one segment.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has devoted its primary efforts to raising capital, internal research and development activities and business development efforts and has incurred significant operating losses and negative cash flows from operations. In August 2020, the Company licensed from Mirati Therapeutics, Inc. development and commercialization rights to an allosteric inhibitor program directed towards the polycomb repressive complex 2 (PRC2) and in October 2020, the Company licensed from Voronoi, Inc. development and commercialization rights to a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 insertion mutations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had an accumulated deficit of $166.4 million. Through December 31, 2020, all of the Company’s financial support has been provided by proceeds from the issuance of common stock and from the sale of convertible preferred stock.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Company continues its expansion, it may seek additional financing and/or strategic investments, however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. The accompanying financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from <span style="color:#000000;">the date of the issuance of these financial statements. </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering and Related Transaction</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 28, 2020, the Company completed an initial public offering (IPO) selling 8,625,000 shares of common stock, which included the full exercise by the underwriters of their option to purchase up to 1,125,000 additional shares, at a price of $16.00 per share resulting in gross proceeds of $138.0 million. After deducting underwriting discounts and commissions and other offering expenses related to the IPO of $12.8 million, the net proceeds to the Company from the transaction were $125.2 million. In connection with the IPO, all shares of convertible preferred stock outstanding at the time of the IPO converted into 19,278,606 shares of common stock. On April 21, 2020, the Company amended its certificate of incorporation to effect a one-for-<span style="-sec-ix-hidden:F_000319">four</span> reverse stock split of its issued and outstanding common and convertible preferred stock. The accompanying financial statements and related notes give retroactive effect, where applicable, to the reverse stock split. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Secondary Public Offering</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 17, 2020, the Company completed a secondary public offering selling 5,796,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase up to 756,000 additional shares, at a price of $23.00 per share, resulting in gross proceeds of $133.3 million. After deducting underwriting discounts and commissions and other offering expenses related to the secondary public offering of approximately $8.5 million, the net proceeds to the Company from the transaction were $124.8 million.</p>
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-166400000
CY2020	oric	Liquid Investments Maturity Period LiquidInvestmentsMaturityPeriod	P90D
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. <span style="color:#000000;">These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates.</span></p>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and short-term investments that are recorded on its balance sheets. The Company mitigates its risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits its exposure.</p>
CY2020Q4	oric	Property Plant And Equipment Impairment Loss PropertyPlantAndEquipmentImpairmentLoss	0
CY2019Q4	oric	Property Plant And Equipment Impairment Loss PropertyPlantAndEquipmentImpairmentLoss	0
CY2018Q4	oric	Property Plant And Equipment Impairment Loss PropertyPlantAndEquipmentImpairmentLoss	0
CY2020	us-gaap	Deferred Compensation Arrangement With Individual Maximum Contractual Term1 DeferredCompensationArrangementWithIndividualMaximumContractualTerm1	P10Y
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-73703000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-26883000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-21363000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21942476
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1899348
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1734115
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.36
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-14.15
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-12.32
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3996174
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21962047
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15644656
CY2020Q3	oric	Number Of Licensed Products Obliged To Develop And Commercialize NumberOfLicensedProductsObligedToDevelopAndCommercialize	1
CY2020Q4	oric	Number Of Licensed Products Obliged To Develop And Commercialize NumberOfLicensedProductsObligedToDevelopAndCommercialize	1
CY2019Q4	oric	Accrued Clinical And Manufacturing Costs AccruedClinicalAndManufacturingCosts	963000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	904000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6466000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5756000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4485000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3515000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1981000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2241000
CY2020	us-gaap	Depreciation Depreciation	1000000.0
CY2019	us-gaap	Depreciation Depreciation	1000000.0
CY2018	us-gaap	Depreciation Depreciation	900000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3723000
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1883000
CY2020Q4	oric	Accrued Clinical And Manufacturing Costs AccruedClinicalAndManufacturingCosts	3072000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	617000
CY2020Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	546000
CY2019Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	495000
CY2019Q4	oric	Accrued Deferred Financing Costs Current AccruedDeferredFinancingCostsCurrent	1244000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8245000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5202000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	215185000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	215154000
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	18
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	oric	Fair Value Assets Level2 To Level3 Transfers Amount FairValueAssetsLevel2ToLevel3TransfersAmount	0
CY2020Q4	oric	Fair Value Assets Level3 To Level2 Transfers Amount FairValueAssetsLevel3ToLevel2TransfersAmount	0
CY2020Q4	oric	Fair Value Assets Level1 To Level3 Transfers Amount FairValueAssetsLevel1ToLevel3TransfersAmount	0
CY2020Q4	oric	Fair Value Assets Level3 To Level1 Transfers Amount FairValueAssetsLevel3ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2019Q4	oric	Fair Value Assets Level2 To Level3 Transfers Amount FairValueAssetsLevel2ToLevel3TransfersAmount	0
CY2019Q4	oric	Fair Value Assets Level3 To Level2 Transfers Amount FairValueAssetsLevel3ToLevel2TransfersAmount	0
CY2019Q4	oric	Fair Value Assets Level1 To Level3 Transfers Amount FairValueAssetsLevel1ToLevel3TransfersAmount	0
CY2019Q4	oric	Fair Value Assets Level3 To Level1 Transfers Amount FairValueAssetsLevel3ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	20348788
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	19278606
CY2020Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	19278606
CY2020Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2683441
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.75
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1599409
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.86
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	117093
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.11
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	169583
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	12.96
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3996174
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.03
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	99107000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1249351
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.07
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	38465000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2700000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2020Q4	oric	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase	6072
CY2019Q4	oric	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase	29579
CY2018Q4	oric	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesSubjectToRepurchase	121794
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q4	us-gaap	Share Price SharePrice	1.60
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.99
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.01
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.41
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5300000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1100000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	500000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	20600000
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6900000
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2300000
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y4M24D
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y4M24D
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5278000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1094000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	469000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15478000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5647000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4487000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5158000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2351000
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1465000
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-280000
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	17000
CY2018	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-15000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	692000
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	663000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20916000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8673000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6536000
CY2020	us-gaap	Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	94000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36740000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24380000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17353000
CY2020Q4	oric	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	3319000
CY2019Q4	oric	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	3319000
CY2018Q4	oric	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	2147000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	214000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	353000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	491000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	2636000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	771000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	255000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6836000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	49745000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28823000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20246000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49507000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28583000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19910000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	238000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	240000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	336000
CY2020Q4	oric	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	238000
CY2019Q4	oric	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	240000
CY2018Q4	oric	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	336000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49500000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20900000
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	130800000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	800000
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1942000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	686000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2628000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0

Files In Submission

Name	View Source	Status
0001564590-21-014865-index-headers.html	Edgar Link	pending
0001564590-21-014865-index.html	Edgar Link	pending
0001564590-21-014865.txt	Edgar Link	pending
0001564590-21-014865-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gpty1lksmhba000001.jpg	Edgar Link	pending
gpty1lksmhba000002.jpg	Edgar Link	pending
gpty1lksmhba000003.jpg	Edgar Link	pending
gpty1lksmhba000004.jpg	Edgar Link	pending
gpty1lksmhba000005.jpg	Edgar Link	pending
gpty1lksmhba000006.jpg	Edgar Link	pending
gpty1lksmhba000007.jpg	Edgar Link	pending
gpty1lksmhba000008.jpg	Edgar Link	pending
gpty1lksmhba000009.jpg	Edgar Link	pending
gpty1lksmhba000010.jpg	Edgar Link	pending
gpty1lksmhba000011.jpg	Edgar Link	pending
gpty1lksmhba000012.jpg	Edgar Link	pending
gpty1lksmhba000013.jpg	Edgar Link	pending
gpty1lksmhba000014.jpg	Edgar Link	pending
gpty1lksmhba000015.jpg	Edgar Link	pending
gpty1lksmhba000016.jpg	Edgar Link	pending
gpty1lksmhba000017.jpg	Edgar Link	pending
gpty1lksmhba000018.jpg	Edgar Link	pending
gpty1lksmhba000019.jpg	Edgar Link	pending
gpty1lksmhba000020.jpg	Edgar Link	pending
gpty1lksmhba000021.jpg	Edgar Link	pending
gpty1lksmhba000022.jpg	Edgar Link	pending
gpty1lksmhba000023.jpg	Edgar Link	pending
gpty1lksmhba000024.jpg	Edgar Link	pending
gpty1lksmhba000025.jpg	Edgar Link	pending
gpty1lksmhba000026.jpg	Edgar Link	pending
gpty1lksmhba000027.jpg	Edgar Link	pending
gpty1lksmhba000028.jpg	Edgar Link	pending
gpty1lksmhba000029.jpg	Edgar Link	pending
gpty1lksmhba000030.jpg	Edgar Link	pending
gpty1lksmhba000031.jpg	Edgar Link	pending
gpty1lksmhba000032.jpg	Edgar Link	pending
gpty1lksmhba000033.jpg	Edgar Link	pending
gpty1lksmhba000034.jpg	Edgar Link	pending
gpty1lksmhba000035.jpg	Edgar Link	pending
gpty1lksmhba000036.jpg	Edgar Link	pending
gpty1lksmhba000037.jpg	Edgar Link	pending
gpty1lksmhba000038.jpg	Edgar Link	pending
gpty1lksmhba000039.jpg	Edgar Link	pending
gpty1lksmhba000040.jpg	Edgar Link	pending
gpty1lksmhba000041.jpg	Edgar Link	pending
gpty1lksmhba000042.jpg	Edgar Link	pending
gpty1lksmhba000043.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oric-10k_20201231.htm	Edgar Link	pending
oric-10k_20201231_htm.xml	Edgar Link	completed
oric-20201231.xsd	Edgar Link	pending
oric-20201231_cal.xml	Edgar Link	unprocessable
oric-20201231_def.xml	Edgar Link	unprocessable
oric-20201231_lab.xml	Edgar Link	unprocessable
oric-20201231_pre.xml	Edgar Link	unprocessable
oric-ex231_2434.htm	Edgar Link	pending
oric-ex311_8.htm	Edgar Link	pending
oric-ex312_9.htm	Edgar Link	pending
oric-ex321_6.htm	Edgar Link	pending
oric-ex322_7.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORIC
Oric Pharmaceuticals, Inc. Stock $oric

2021 Q1 Form 10-K Financial Statement

#000156459021014865 Filed on March 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORIC Oric Pharmaceuticals, Inc. Stock $oric

2021 Q1 Form 10-K Financial Statement

#000156459021014865 Filed on March 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORIC
Oric Pharmaceuticals, Inc. Stock $oric